Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 20,881-20,892 of 23,847
Drug study icon
CompletedEUCTR 2006-003597-10

GW876008, Placebo and Active Control (Paroxetine) for anxiety

This study is completed in Germany, in Finland, and in Sweden. It is testing GW876008, Placebo and Active Control (Paroxetine) for anxiety.

In Germany
AnxietyOther
Countries
Germany, Finland, Sweden
Sponsor
GlaxoSmithKline Research & Development
Condition
Anxiety
Behavioral study icon
CompletedNCT06081634

Study Efficacy of Enhancing Cognitive Reserve in people with a First Bipolar Episode

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

In Barcelona
BipolarityBehavioralFrom 18 Years to 40 Years
Countries
Spain
Sponsor
Hospital Clinic of Barcelona
Condition
Bipolarity
Drug study icon
CompletedNCT00134459

Study Evaluating Bifeprunox in Depression in bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Birmingham
Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Bipolarity, Depression
Drug study icon
TerminatedNCT00366327

Study Evaluating Bifeprunox in people with Schizophrenia.

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
SchizophreniaDrugFrom 18 Years to 66 Years
Countries
United States
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Schizophrenia
Drug study icon
CompletedNCT00488618

Study Evaluating Cariprazine (RGH-188) in the Treatment of people with Acute Mania

This study exists to understand how the medication RGH-188 holds up over time after the earliest research stage. Researchers are trying to understand how people respond to the medication RGH-188 in practice and what may need to be adjusted.

In St Louis
BipolarityDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Forest Laboratories
Condition
Bipolarity
Drug study icon
CompletedNCT06126497

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

This study exists to understand whether a digital app or remote support tool is both safe enough and useful enough to take further. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

Multiple locations, including Bellflower
DepressionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Suven Life Sciences Limited
Condition
Depression
Drug study icon
TerminatedNCT00581243

Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients

This study exists to better understand the safety of the medication SLV-313 and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

Location not clearly listed
SchizophreniaDrugFrom 18 Years to 50 Years
Countries
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.